Browse Interferon beta topic

Subtopics (13)

Articles

1-41 out of 41 article(s)

Title	Author	Type	Date	Words
Betaferon's Relapsing-Remitting Effect on MS Similar in Different Doses.			Sep 12, 2009	358
Fewer Injection Site Reactions in Patients Using AVONEX[R] Versus Sub-cutaneous Interferon and Glatiramer Acetate for the Treatment of Multiple Sclerosis.			Sep 11, 2009	902
Biogen Idec Showcases More Than 70 Data Presentations at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.			Sep 2, 2009	1882
Research and Markets: Biosimilars Series: Forecast Analysis for Biosimilar Epoetin Alpha, Filgrastim, Interferon Beta, Interferon Alpha, Human Growth Hormone, and Insulin-Glargine.			Jul 20, 2009	399
Biogen Idec Receives Fast Track Designation from FDA for PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis.			Jul 8, 2009	504
Biogen Idec Announces First Patient Enrolled in the Global Phase III Study of PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis.			Jun 22, 2009	795
First Ten-Year Follow-Up Shows That Treatment with AVONEX[R] Leads to Long-Term Benefits in Early Multiple Sclerosis Patients.			Apr 30, 2009	716
Biogen Idec Showcases Leading Multiple Sclerosis Franchise and Pipeline at the 61st Annual Meeting of the American Academy of Neurology.			Apr 15, 2009	1816
Biopartners to Appeal the CHMP's Negative Opinion on Its Novel Interferon beta-1a.			Feb 19, 2009	332
BOLDER BIOTECHNOLOGY GETS $1.6 MIL NIH GRANT FOR MS DRUG.			Nov 1, 2008	322
Biogen Idec Features Data on AVONEX(R) and TYSABRI(R) and Showcases the Company's Multiple Sclerosis Development Pipeline at the World Congress On Treatment and Research in Multiple Sclerosis.			Sep 18, 2008	1850
New Long-Term Data Show That Patients Taking AVONEX(R) for up to 15 Years Experience Reduced Disability Progression and Improved Quality of Life.			Sep 18, 2008	768
Enrollment Complete in 15-Year Long-Term Follow-Up Study Evaluating Impact of AVONEX(R) in Patients with Relapsing Multiple Sclerosis.		Report	Aug 27, 2008	710
New Data Show Patients Using AVONEX(R) Reported Less Sick Leave and Short-Term Disability Costs Than Patients Using Copaxone(R).			Jun 2, 2008	867
New Data Show Treatment of Multiple Sclerosis (MS) with AVONEX(R) (interferon Beta-1a) Enhances Quality of Life.		Clinical report	Apr 16, 2008	702
Study Shows that High-Dose, High-Frequency Interferon Produces no Additional Benefit on Efficacy Compared to AVONEX(R) (interferon beta-1a) in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS).		Clinical report	Apr 15, 2008	689
Study Showed Patients Using COPAXONE(R) Had Significantly Lower Risk of Relapse and Lower Medical Costs Compared to Patients Using Rebif(R) in Relapsing-Remitting Multiple Sclerosis (RRMS).			Oct 25, 2007	1084
COPAXONE(R) Significantly Decreases Disease Activity in Patients Who Switched from Interferon Beta (INFb) Due to Development of Neutralizing Antibodies (NAbs).			Oct 23, 2007	1242
COPAXONE(R) Significantly Decreases Disease Activity in Patients Who Switched from Interferon Beta (IFNb) Due to Development of Neutralizing Antibodies (NAbs).			Oct 23, 2007	1184
Biogen Idec Announces Multiple Sclerosis Franchise and Pipeline Presentations at the European Committee for Treatment and Research of Multiple Sclerosis.			Oct 11, 2007	1447
Biopartners Submits Its Novel Interferon beta-1a, Biferonex(R), To The EMEA.			Aug 20, 2007	359
Biogen Idec Launches New AVONEX(R) Nurse Services Program.			Apr 26, 2007	927
New One-Year Pharmacoeconomic Study Shows AVONEX(R) is Cost-Effective Relative to Other Interferon Therapies for Multiple Sclerosis.			Apr 13, 2007	742
First Pharmacoeconomic Analysis with Long-Term Data Showed COPAXONE(R) Was More Cost-Effective Than Interferon Beta Therapies for Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS).			Apr 11, 2007	1471
Interferon Beta DNA Treatment Delivered with Ichor Technology Reduces Atherosclerosis Progression in Mice.			Mar 26, 2007	641
Multiple sclerosis: searching for solutions.	Zipes, Douglas	Brief Article	Sep 1, 2003	271
It's official: Medicare covers Avonex. (news).		Brief Article	Oct 1, 2002	184
INCOMIN results favor frequent interferon dosage. (news).		Brief Article	Oct 1, 2002	214
The efficacy of a herbal medicine (Mao-to) in combination with intravenous natural interferon-[beta] for patients with chronic hepatitis C, genotype 1b and high viral load: a pilot study.	Kainuma, M.; Ogata, N.; Kogure, T.; Kohta, K.; Hattori, N.; Mitsuma, T.; Terasawa, K.		Jul 1, 2002	4178
Rebif [in context].	King, Martha		Jun 22, 2002	1987
FDA approves Rebif. (News).		Brief Article	Jun 22, 2002	312
FDA approves room-temperature Betaseron. (News).		Brief Article	Jun 22, 2002	112
Avonex for people who might get MS?		Product/Service Evaluation	Jan 1, 2001	281
Rebif and Avonex go head-to-head.		Product/Service Evaluation	Jan 1, 2000	498
Rebif trial disappointing for secondary-progressive MS.		Product/Service Evaluation	Sep 22, 1999	252
FDA decision on Rebif.			Mar 22, 1999	142
Two promising MS drugs move toward marketplace.			Jan 1, 1995	512
More hope, more questions.			Jan 1, 1995	582
Betaseron near formal approval.			Jun 22, 1993	503
About Betaseron ....			Jun 22, 1993	417
The people behind the drug.	Eastwood, Abe		Jun 22, 1993	399

Browse  Interferon beta topic

Subtopics (13)

Articles

Browse Interferon beta topic